# Patrick Ansems

Patrick Ansems writes about digital transformation in life sciences, especially using digital twins and connected data to link pharmaceutical research, manufacturing and operations.

- Profile: https://b2binfluencer.marketing/creators/patrick-ansems/
- LinkedIn: https://www.linkedin.com/in/patrickansems
- LinkedIn followers: 2,924
- Topics: artificial-intelligence
- Based on 11 dated posts, latest 2026-10-01

## Summary

Patrick Ansems is most useful for explaining how digital twins, digital threads and AI connect pharma research, manufacturing and operations.

- Best for: A life sciences software vendor selling digital-twin and digital-thread products for pharma manufacturing.
- Not for: A consumer health or wellness brand seeking high-volume paid social reach and direct response.
- Check first: Confirm scope, terms, disclosure, LinkedIn analytics and recent performance before committing budget.

### Takeaways

- A digital twin is a snapshot; a closed loop is the strategy.
- The Digital Organism framework has four parts: Mind, Heart, Body and Soul.
- AI insights need decision-making context; governance, collaboration and people matter to execution.

## Main ideas

- **A digital twin is a snapshot; a closed loop is the strategy**: Patrick Ansems argues that a static digital twin of the lab or factory cannot support personalized medicine at scale. The value comes from keeping the two worlds in real-time conversation: bench intelligence adjusts manufacturing parameters, while manufacturing deviations feed back into R&D to shape the next formulation. Another post casts the digital thread as the “heart” that carries scientific intent from the lab to the factory floor without losing its beat. It ends by asking how others handle handovers between digitized silos, identifying the handover as an unresolved problem.
- **The Digital Organism framework**: Patrick Ansems uses a four-layer model to organize arguments about life sciences transformation. The Mind covers AI, simulation, knowledge graphs and predictive intelligence. The Heart is the digital thread or orchestration layer. The Body covers laboratories, manufacturing, automation and physical execution. The Soul covers people, governance, compliance, trust and patient impact. The framework diagnoses whether an organization is building a one-off project or an operating organism.
- **Eroom's Law and the execution gap: AI is a context problem**: Patrick Ansems argues that life sciences digital transformation stalls not because data is scarce, but because organizations cannot turn signals into decisions and decisions into action quickly enough. The posts cite Eroom’s Law, 25% of manufacturing capacity trapped, and more than $300B at risk; they also describe disconnected IT projects as a poor fit for the continuous race to scale therapies. The synthesis at the Arvato Systems forum: 'AI is not a data problem. It is a context problem.' Ansems attributes Eroom’s Law and the need to absorb AI-generated insights into decision-making to S. M. Richards; “context to action” in manufacturing to Thomas Halfmann; and healthcare data spaces, interoperability, governance and collaboration to Maro Bader and Ralf Heyder. These are the guests’ views; Ansems’s own framing is the context-problem line and the Digital Organism.
- **Demonstration over description: living labs and experience centers**: Patrick Ansems makes the case for showing the connected factory, not just describing it. A post on the updated Siemens Life Sciences Experience Center in Vienna presents its expanded Living Lab and Digi Lab as a mini pharma company, where customers can see discovery, development, manufacturing and operations connected through a digital thread. The challenge is the handover: knowledge moves between scientists, process engineers, manufacturing teams, quality teams, suppliers and regulators; data lives in different systems, and context gets lost. The priority is One Team and One Tech: software, automation and consulting working together around a common purpose.
- **Event synthesis and named collaborators**: A recurring method: attend and recap industry events, connect speakers’ points through a single frame, and credit contributors and host organizations by name. At the Arvato Systems forum, Patrick Ansems summarizes S. M. Richards, Thomas Halfmann, Maro Bader and Ralf Heyder, and thanks Arvato Systems, speakers, panelists and participants. In the Siemens post, they credit Christian Glaser, Dr. Julita Panek and Guillermo Jimeno, describing the project as a One Team and One Tech story. Andrew Whytock appears as co-presenter of the Digital Organism.

## Work to read

- [A Digital Twin is a snapshot. A Closed-Loop is a strategy.](https://www.linkedin.com/posts/patrickansems_lifesciences-digitaltransformation-strategy-activity-7503796236630769682-ku5Q)
- [Siemens Life Sciences Experience Center in Vienna: Living Lab and Digi Lab](https://www.linkedin.com/posts/patrickansems_oneteam-onetech-lifesciences-activity-7511348914781061120-6T18)
- [Most companies are losing the race against time.](https://www.linkedin.com/posts/patrickansems_lifesciences-moleculetomarket-strategyofscale-activity-7508793677469679616-h-YN)
- [11th Life Science Forum: AI is not a data problem. It is a context problem.](https://www.linkedin.com/posts/patrickansems_lifesciences-ai-digitaltransformation-activity-7510892871223382016-1LME)

## Brand relationships

- **Siemens** (employment)
- **Arvato Systems** (mention)

## Partnerships

Patrick Ansems writes about life sciences digital transformation, digital twins, connected data from molecule to market, and events such as the Life Science Forum hosted by Arvato Systems and the Siemens Life Sciences Experience Center in Vienna. The posts don’t specify a sponsorship package, paid partnership format, rate card, deliverables, or official inquiry route. They invite direct messages about connecting molecule to market, but don’t identify that as an official partnership channel. Buyers should confirm the format and terms directly with Patrick Ansems or an official representative before planning a collaboration; event participation and partner mentions aren’t enough to establish them.

## Alternatives

- Dan Lewis: Choose Dan Lewis when the vendor’s buyers work in manufacturing operations, project delivery and CQV rather than R&D architecture, and the goal is a recurring, low-lift publishing cadence instead of one large co-authored piece. Lewis’s post on the Project Farma and PerkinElmer acquisition of SimoTech describes automation and digital manufacturing as connected across the whole facility lifecycle — design, project execution, CQV, start-up, operational readiness and ongoing operations. It frames the value as reducing handoffs and aligning engineering, quality, automation, digital systems and operations around shared objectives. That’s the same buyer problem Patrick Ansems addresses with the digital thread, but from the delivery and execution side, giving the vendor a natural inroad to operations and CQV leaders who sign off on manufacturing software. Lewis also publishes a pharma news roundup covering deals, FDA leadership changes, pricing, manufacturing and funding, creating frequent opportunities for a vendor to be a named source on a development rather than wait for a single flagship collaboration.
- Jason Hier: Choose Jason Hier when the campaign is about portfolio prioritisation, cross-functional alignment or roadmap tooling rather than the manufacturing closed loop. Hier addresses decisions the vendor’s buyer often makes before any technology purchase: how to align research, regulatory, product and commercial goals; prioritise initiatives by strategic value; and visualise dependencies and bottlenecks before they become costly. The posts name a specific method and artefact — a MoSCoW grid for collaborative prioritisation, visual roadmaps on SharpCloud through Roelto — and show a partner tool in use, not just describe it. A vendor selling portfolio, roadmap or portfolio-visualisation software, or whose sale stalls until a pharma organisation agrees on priorities, gets a closer match here than with Ansems, whose framing assumes the manufacturing problem is understood and focuses on how to connect it.
- Bilal Bham: Choose Bilal Bham when the campaign is about commercialisation, regulatory strategy or market access for a modality, and the vendor wants recurring published analysis rather than event recaps. In 'The Amodaia Brief,' Bham takes the fortnight’s developments — a second positive Phase III in generalised anxiety disorder, the first US radioligand therapy approved through an abbreviated generic pathway — and draws out the commercial question: repeatable efficacy, delivery, manufacturing and economics. The 'Narrative Integrity' argument — that regulatory position, CMC, clinical evidence, medical communication and access must all describe the same source of value — offers a positioning argument a vendor could co-author. The format also gives the vendor a named publication to appear in on a predictable cycle. A vendor selling into medical affairs, market access or commercial strategy would find a more natural entry point here than with Ansems.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/